Gilead Sciences reported Q1 earnings of $2.03 per share, beating estimates by $0.12, as revenue rose 4% to $6.96 billion.
Gilead Sciences (NASDAQ:GILD) posted first-quarter adjusted earnings of $2.03 per share, exceeding the $1.91 consensus estimate by $0.12. Revenue climbed 4% year-over-year to $6.96 billion, topping the $6.91 billion forecast.
The company’s HIV portfolio drove growth, with Biktarvy sales rising 7% to $3.36 billion and Descovy revenue surging 38% to $807 million. Yeztugo, a twice-yearly HIV prevention injection, also contributed to the beat.
On May 8, 2026, Truist raised its price target on Gilead to $157 from $155, maintaining a Buy rating. The firm cited the Q1 beat and an upwardly revised FY26 revenue outlook.